Skip to Content

BioTime CEO Dr. Michael West to Present at Stem Cells USA & Regenerative Medicine Congress 2009

ALAMEDA, Calif.--(BUSINESS WIRE)--Nov 12, 2009 - BioTime, Inc. (NYSE Amex: BTIM) Chief Executive Officer Michael West, Ph.D. will give two presentations at the Stem Cells USA & Regenerative Medicine Congress 2009 to be held at The Westin Washington DC City Center Hotel in Washington, DC from November 16-18, 2009. On Tuesday, November 17, Dr. West will discuss applications of stem cell technology for diseases of the skin and bone. Dr. West will provide an update on BioTime's ACTCellerate™ technology platform in cartilage biology and will disclose new data from the Company's fate space screen. Then on Wednesday, November 18, Dr. West will give a presentation during a panel session discussing business models for regenerative medicine. Both presentations will be made available on the Company's website at

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. BioTime's subsidiary OncoCyte Corporation focuses on the therapeutic applications of stem cell technology in cancer. BioTime also plans to develop therapeutic products in China for the treatment of ophthalmologic, skin, musculo-skeletal system and hematologic diseases, including the targeting of genetically modified stem cells to tumors as a novel means of treating currently incurable forms of cancer through its subsidiary BioTime Asia. In addition to its stem cell products, BioTime markets blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment, and other applications. BioTime's lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime can be found on the web at ACTCellerate™ is a trademark licensed to Embryome Sciences, Inc. by Advanced Cell Technology, Inc.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list:



Contact: BioTime, Inc.
Judith Segall, 510-521-3390, ext 301


Posted: November 2009